The Cmo Market Outlook: Emerging markets, key players and future trends

Table of Contents

Executive Summary

• The contract manufacturing market
• CMO market analysis
• Emerging regions in the CMO market
• Key players in the CMO market
• The future of the CMO market

Chapter 1 The contract manufacturing market

• Summary
• Introduction
• Current market drivers
  • Sale of captive plants
  • Cost pressures encourage outsourcing
  • Increasing number of products in development
  • Consolidation in the pharmaceutical industry
  • Increase in biopharmaceuticals market
  • Growth of emerging pharmaceutical markets
• Current market restraints
  • Overcapacity
  • Financial pressures
  • Increased competition - low barriers to entry
  • Conclusions

Chapter 2 CMO market analysis

• Summary
• Introduction
  • Primary manufacturing
  • Secondary manufacturing
• Structure of the CMO market
  • Advantages of small and medium sized vs. large CMOs
• Industry strategies
  • Strategic outsourcing
  • Diversification
  • Biopharmaceutical manufacturing
  • Overcapacity
  • Pilot plants
• Conclusion

Chapter 3 Emerging regions in the CMO market

• Summary
• Introduction
• China
  • Drivers of the Chinese contract manufacturing market
  • Challenges of the Chinese contract manufacturing market
  • China' s regulatory framework
  • Intellectual property protection
  • Counterfeit drugs
  • China' s major contract manufacturing organizations
    • CMOs offering finished drugs services
    • Biopharmaceutical contract manufacturing in China
• India
  • Size of the Indian CMO market
  • Patent situation and implications for foreign direct investment
    • Challenges in current patent law
  • India as a preferred offshoring destination
  • The new, integrated business model of Indian CMOs
    • Challenges facing the CRAMS business model
  • Expansion strategies of India' s major contract manufacturing organizations
  • Conclusions

Chapter 4 Key players in the CMO market

• Summary
• Introduction
• Methodology
• Catalent
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• Lonza
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• Boehringer Ingelheim (BI)
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• DSM
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• Evonik
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• Patheon
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• Jubilant
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• BASF
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• Fareva
  • Company profile
  • Business description
  • Partnering collaborations and recent deals
• Wockhardt
  • Company profile
  • Business description
  • Partnering collaborations and recent deals

Chapter 5 The future of the CMO market

• Summary
• Introduction
• Strategic partnerships
  • Biomanufacturing
  • Disposable equipment
  • Offshoring
  • Market outlook

Chapter 6 Appendix

• Selected bibliography
• Index

List of Figures

• Figure 1.1: Contract manufacturing market ($bn), 2006-14e
• Figure 1.2: Pharmaceutical manufacturing process
• Figure 1.3: Services performed by CMOs and CDMOs
• Figure 1.4: Number of FDA approvals (NCEs), 1990-2008
• Figure 1.5: Number of products in development by phase, 1998-2009
• Figure 1.6: The contract biomanufacturing market ($bn), 2009-14e
• Figure 2.7: Stages of pharmaceutical manufacturing
• Figure 2.8: Outsourced biological vs. non-biological manufacturing market, 2009-14e
• Figure 2.9: Sponsors employing strategic outsourcing (%)
• Figure 2.10: Installed bioreactor capacity (KL), 2006-13e
• Figure 2.11: Geographical distribution of bioreactor capacity (%), 2008-13e
• Figure 3.12: Share of pharmaceutical sales growth by region, 2006-09f
• Figure 3.13: Chinese API exports, $bn 2007-14e
• Figure 3.14: Chinese finished form pharmaceuticals exports 2007-14e, $bn
• Figure 3.15: India' s finished dose exports ($bn), 2007-14e
• Figure 3.16: India' s API exports ($bn), 2007-14e
• Figure 3.17: Indian CRAMS market ($bn), 2007-14e
• Figure 3.18: Three waves of Indian opportunity
• Figure 5.19: Expectations of outsourcing expenditure change, 2009

List of Tables

• Table 1.1: New entrants in the pharmaceutical CMO market
• Table 2.2: Structure of the CMO industry
• Table 2.3: Cost of inaccurate capacity planning
• Table 3.4: Selected partnering agreements with Chinese manufacturers
• Table 3.5: Selected contract manufacturing/ research deals in India
• Table 3.6: Strategic options for Indian pharmaceutical companies